How reducing labor time can save on your cell therapy manufacturing costs

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In the early clinical development stage of autologous cell therapy manufacture, labor costs often dominate the overall cost of goods (CoGs) sold. However, as manufacturing scales out, the cost of materials — including media and reagents, consumables, and viral vectors — increases as a percentage of the total CoGs. Ultimately, economies of scale can be achieved with autologous cell therapy processing. However, in order to widen access to these life-saving treatments, it’s crucial that manufacturers utilize solutions that can support reductions in labor costs.

In this webinar, our speakers will explain how you can reduce labor time for certain critical steps of autologous cell therapy manufacturing by using automated and closed systems. They’ll compare operator tasks in a standard process versus a process using Cytiva systems for specific steps, such as cell expansion, mononuclear cell enrichment, and cryopreservation.

• Identify the challenges faced in the industry today
• Understand the benefits of automated and closed systems
• Discover how Cytiva systems such as Xuri™ Cell Expansion System W25, Sepax™ C-Pro system, and VIA Freeze™ instruments can help to reduce labor time and save costs

Yen Kong

Field Application Scientist for Cell Therapy, USCAN Cytiva

Dr. Yen Kong is currently a Field Application Scientist based in Marlborough, Massachusetts supporting cell therapy customers in the US and Canada on their process development needs. Before his current role, Yen was a Development Scientist in R&D involved with developing the next generation bioreactor for closed and automated expansion of cell therapies.

Jeeheon Kang

GM Cell Therapy FAS Leader, APAC Cytiva

Jeeheon received a Ph.D. in genetic engineering from Seoul National University, worked as a project manager at Asan medical center, and has been working as a Cytiva Cell Therapy Field Application Specialist for four years. Based on her knowledge of the cell therapy equipment from Cytiva, she is conducting customer seminars, trainings, and demonstration experiments to support customers for better therapy.

Janôt Schoep

Field Application Specialist for Cell Therapy, EMEA Cytiva

Prior to joining Cytiva as a Field Application Specialist nearly 1,5 years ago, Janôt was working inside a GMP manufacturing facility, being hands-on with patient material to create several cell therapies that are currently in clinical and commercial phase. He has experienced the benefits of using automated instruments that can standardize and close the manufacturing process and reduce contamination risk.

Watch now

SPEAKERS

Yen Kong

Field Application Scientist for Cell Therapy, USCAN Cytiva

Jeeheon Kang

GM Cell Therapy FAS Leader, APAC Cytiva

Janôt Schoep

Field Application Specialist for Cell Therapy, EMEA Cytiva

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 64

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 43

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

B Yevgeniy, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 42

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 35

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 29

Days

Register